MyFinsight
Home
Blog
About
Cash and cash
equivalents
$4,546,140
Accounts receivable, net
$291,486
Prepaid expenses and
other current assets
$126,961
Inventory
$111,036
Total property and
equipment
$540,451
Total current assets
$5,075,623
Right-of-use assets, net
$519,302
License agreement, net
$265,518
Intangible asset, net
$205,985
Property and equipment,
net
$33,700
Other assets
$23,057
Less accumulated
depreciation
$506,751
Total assets
$6,123,185
Total liabilities,
contingently redeemable...
$6,123,185
Total liabilities
$2,963,877
Total stockholders
equity (deficit)
$1,620,700
Series e convertible
preferred stock, 0.01 par...
$1,538,608
Accumulated deficit
-$36,928,398
Total current
liabilities
$2,551,236
Total long-term
liabilities
$412,641
Additional paid-in capital
$38,426,586
Common stock, 0.01 par
value 50,000,000...
$122,512
Accounts payable
$1,026,809
Accrued liabilities
$743,001
Deferred revenue current
$467,033
Operating lease liability
current
$192,731
Accrued dividends
series e convertible...
$121,662
Operating lease liability
long term
$379,717
Deferred revenue
long-term
$32,924
Back
Back
Balance Sheet
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)
source: myfinsight.com